Histoplasmosis in the United Kingdom: Diagnosis and management in a non-endemic setting
Clinical Infection in Practice · 2026-08 · 31 · 100718
DOI: 10.1016/j.clinpr.2026.100718 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infection in Practice, 2026-08. Verfasst von Lottie Brown und 6 weiteren Autor:innen. Die Arbeit nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The invasive fungal disease histoplasmosis poses a significant diagnostic challenge in non-endemic settings like the United Kingdom (UK). Once considered endemic only in the Americas, histoplasmosis is now recognised to be widespread across large parts of Africa, Asia and parts of Oceania, as well as pockets of southern Europe. This likely reflects improved diagnostic capacity and the introduction of Histoplasma -specific antigen testing in research settings, rather than true geographic expansion. In non-endemic settings like the UK, histoplasmosis may be overlooked or mistaken for more commonly encountered diseases such as tuberculosis, leading to delays in initiating appropriate antifungal therapy. This diagnostic challenge is compounded by the highly variable clinical manifestations of histoplasmosis, which depend on exposure burden and host immune status, ranging from localised pulmonary disease to severe disseminated, multi-organ infection that may present years to decades after exposure. In non-endemic settings, diagnostic pathways for histoplasmosis are hampered by limited clinical awareness among healthcare providers, non-specific clinical and radiological manifestations, the poor sensitivity and prolonged turnaround time of culture-based methods, and restricted availability of rapid Histoplasma -specific serological tests ( Histoplasma antibody and antigen tests currently available at one and two laboratories in the UK, respectively). These challenges have significant clinical consequences: delay to diagnosis and initiation of antifungal therapy are associated with high mortality from disseminated histoplasmosis. This review provides an overview of histoplasmosis for clinicians, particularly those practicing in the UK and other non-endemic settings, encompassing epidemiology, pathogen biology, clinical presentations, and recommended diagnostic and management approach.
Zitieren
APA
Brown, L., Bakrania, P., Harrison, A., Mehra, R., Borman, A., O'Hara, G., & Stone, N. R. (2026). Histoplasmosis in the United Kingdom: Diagnosis and management in a non-endemic setting. Clinical Infection in Practice, 31, 100718. https://doi.org/10.1016/j.clinpr.2026.100718
Vancouver
Brown L, Bakrania P, Harrison A, Mehra R, Borman A, O'Hara G, et al. Histoplasmosis in the United Kingdom: Diagnosis and management in a non-endemic setting. Clinical Infection in Practice. 2026;31:100718. doi:10.1016/j.clinpr.2026.100718
BibTeX
@article{Brown2026,
author = {Brown, Lottie and Bakrania, Prijay and Harrison, Annabelle and Mehra, Rohan and Borman, Andrew and O'Hara, Geraldine and Stone, Neil R.H.},
title = {Histoplasmosis in the United Kingdom: Diagnosis and management in a non-endemic setting},
journal = {Clinical Infection in Practice},
year = {2026},
volume = {31},
pages = {100718},
doi = {10.1016/j.clinpr.2026.100718}
}
EUVIMED